Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-04-2009 | Preclinical Study

The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

Authors: A-Yong Cao, Juan Huang, Zhen Hu, Wen-Feng Li, Zhong-Liang Ma, Li-Li Tang, Bin Zhang, Feng-Xi Su, Jie Zhou, Gen-Hong Di, Kun-Wei Shen, Jiong Wu, Jin-Song Lu, Jian-Min Luo, Wen-Tao Yuan, Zhen-Zhou Shen, Wei Huang, Zhi-Ming Shao

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C>T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C>T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.
Literature
1.
go back to reference Li WF, Hu Z, Rao NY et al. (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat doi:10.1007/s10549-007-9708-3 (in press) Li WF, Hu Z, Rao NY et al. (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat doi:10.​1007/​s10549-007-9708-3 (in press)
2.
go back to reference Xia B, Sheng Q, Nakanishi K, Ohashi A et al (2007) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719–729CrossRef Xia B, Sheng Q, Nakanishi K, Ohashi A et al (2007) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719–729CrossRef
4.
go back to reference Xia B, Dorsman JC, Ameziane N et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161PubMedCrossRef Xia B, Dorsman JC, Ameziane N et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161PubMedCrossRef
5.
go back to reference Reid S, Schindler D, Hanenberg H et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162–164PubMedCrossRef Reid S, Schindler D, Hanenberg H et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162–164PubMedCrossRef
6.
go back to reference Howlett NG (2007) Fanconi anemia: Fanconi anemia, breast and embryonal cancer risk revisited. Eur J Hum Genet 15:715–7PubMedCrossRef Howlett NG (2007) Fanconi anemia: Fanconi anemia, breast and embryonal cancer risk revisited. Eur J Hum Genet 15:715–7PubMedCrossRef
8.
go back to reference Offit K (2006) BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 98:1675–1677PubMedCrossRef Offit K (2006) BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 98:1675–1677PubMedCrossRef
9.
go back to reference Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167PubMedCrossRef Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167PubMedCrossRef
10.
go back to reference García MJ, Fernández V, Osorio A et al. (2008) Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat doi:10.1007/s10549–008-9945-0 (in press) García MJ, Fernández V, Osorio A et al. (2008) Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat doi:10.​1007/​s10549–008-9945-0 (in press)
11.
go back to reference Foulkes WD, Ghadirian P, Akbari MR et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French–Canadian women. Breast Cancer Res 9:R83PubMedCrossRef Foulkes WD, Ghadirian P, Akbari MR et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French–Canadian women. Breast Cancer Res 9:R83PubMedCrossRef
12.
go back to reference Erkko H, Xia B, Nikkilä J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319PubMedCrossRef Erkko H, Xia B, Nikkilä J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319PubMedCrossRef
13.
go back to reference Tischkowitz M, Xia B, Sabbaghian N et al (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104:6788–6793PubMedCrossRef Tischkowitz M, Xia B, Sabbaghian N et al (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104:6788–6793PubMedCrossRef
14.
go back to reference Offit K (2000) Are BRCA1- and BRCA2-associated breast cancers different? J Clin Oncol 18:104–106 Offit K (2000) Are BRCA1- and BRCA2-associated breast cancers different? J Clin Oncol 18:104–106
15.
go back to reference Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107–112 Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107–112
16.
17.
go back to reference Klein B, Weirich G, Brauch H (2001) DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations. Hum Genet 108:376–384PubMedCrossRef Klein B, Weirich G, Brauch H (2001) DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations. Hum Genet 108:376–384PubMedCrossRef
18.
go back to reference Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439–474PubMedCrossRef Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439–474PubMedCrossRef
19.
go back to reference Song CG, Hu Z, Wu J et al (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol 32:617–626CrossRef Song CG, Hu Z, Wu J et al (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol 32:617–626CrossRef
20.
go back to reference Hu Z, Wu J, Liu CH et al (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22:104PubMedCrossRef Hu Z, Wu J, Liu CH et al (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22:104PubMedCrossRef
Metadata
Title
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives
Authors
A-Yong Cao
Juan Huang
Zhen Hu
Wen-Feng Li
Zhong-Liang Ma
Li-Li Tang
Bin Zhang
Feng-Xi Su
Jie Zhou
Gen-Hong Di
Kun-Wei Shen
Jiong Wu
Jin-Song Lu
Jian-Min Luo
Wen-Tao Yuan
Zhen-Zhou Shen
Wei Huang
Zhi-Ming Shao
Publication date
01-04-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0036-z

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine